If you have been reading about growth hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
The gateway hypothesis is the idea that using less harmful drugs can lead to more harmful ones. Some users who begin by vaping will go on to also smoke traditional cigarettes. People with mental illnesses, who as a group are more susceptible to nicotine addiction, are at particularly high risk of dual use. The correlation between vaping and subsequent smoking does not necessarily imply a causal effect. Users may have underlying characteristics that predispose them to nicotine use. There is a genetic association between smoking, vaping, gambling, promiscuity, and risk-taking behaviors. Young people with poor executive function vape, smoke, and drink alcohol more than their peers. E-cigarette users are also more likely to use both cannabis and unprescribed Adderall or Ritalin. Longitudinal studies of e-cigarettes and smoking have been criticized for failing to adequately control for these and other confounding factors. Smoking rates have declined as e-cigarette use has grown, especially among young people. This may be because there is little gateway effect at the population level, or because of anti-smoking interventions.
In the United States, it is against federal regulations for supplement manufacturers to claim that their products prevent or treat any disease. Companies are allowed to use what is referred to as "Structure/Function" wording if there is substantiation of scientific evidence for a supplement providing a potential health effect. An example would be "_____ helps maintain healthy joints", but the label must bear a disclaimer that the Food and Drug Administration (FDA) "has not evaluated the claim" and that the dietary supplement product is not intended to "diagnose, treat, cure or prevent any disease", because only a medication can legally make such a claim. The FDA enforces these regulations as well as prohibiting the sale of supplements and supplement ingredients that are dangerous, or supplements not made according to standardized good manufacturing practices (GMPs). The European Commission has established harmonized rules to help insure that food supplements in the European Union are safe and appropriately labeled.
=== Ion-exchange chromatography === EDTA was used in separation of the lanthanide metals by ion-exchange chromatography. Perfected by F. H. Spedding et al. in 1954, the method relies on the steady increase in stability constant of the lanthanide EDTA complexes with atomic number. Using sulfonated polystyrene beads and Cu2+ as a retaining ion, EDTA causes the lanthanides to migrate down the column of resin while separating into bands of pure lanthanides. The lanthanides elute in order of decreasing atomic number. Due to the expense of this method, relative to countercurrent solvent extraction, ion exchange is now used only to obtain the highest purities of lanthanides (typically greater than 99.99%).
Sources: en.wikipedia.org
The employees were young men: handsome jocks in form-fitting red-and-white striped soccer shirts; when a patron was celebrating a birthday, the entire restaurant crew came around with a cake and sang TGI Fridays' traditional birthday song. Footage of interviews with patrons from this TGI Fridays was featured in Robert Downey Sr.'s film No More Excuses (1968). The first location closed in 1994 and became a British-style pub called "Baker Street". Although Malachy McCourt's nearby Malachy's singles bar preceded TGI Fridays and Stillman credited the media for creating the term, he had unintentionally created one of the first singles bars. It benefited from the near-simultaneous availability of the birth-control pill and Betty Friedan's book The Feminine Mystique:
Froud, Kristina E.; Wardhaugh, Tina; Banks, Duncan; Saffrey, M. Jill; Stewart, Michael G. (2010). "Colostrinin™ Alleviates Amyloid-β Induced Toxicity in Rat Primary Hippocampal Cultures" (PDF). Journal of Alzheimer's Disease. 20 (2): 423–426. doi:10.3233/JAD-2010-1382. PMID 20164569.
Brian Christian wrote that experts have pivoted "from the question of 'what they know' to the question of 'what they're doing with it'." Generative AI is often trained on unlicensed copyrighted works, including in domains such as images or computer code; the output is then used under the rationale of "fair use". Experts disagree about how well and under what circumstances this rationale will hold up in courts of law; relevant factors may include "the purpose and character of the use of the copyrighted work" and "the effect upon the potential market for the copyrighted work". Website owners can indicate that they do not want their content scraped via a "robots.txt" file. However, some companies will scrape content regardless because the robots.txt file has no real authority. In 2023, leading authors (including John Grisham and Jonathan Franzen) sued AI companies for using their work to train generative AI. Another discussed approach is to envision a separate sui generis system of protection for creations generated by AI to ensure fair attribution and compensation for human authors.
Sources: en.wikipedia.org
=== Other conditions === Modafinil has been investigated for several other conditions with inconclusive or preliminary results. Preliminary research is examining modafinil for excessive daytime sleepiness in myotonic dystrophy, though it is not approved for this use and results are debated. Modafinil has also been studied for disorders of consciousness, but observational reports have produced mixed results.
=== 6 May === The RSF launched another series of drone strikes on Port Sudan. Six people were killed by RSF shelling on the Abu Shouk camp. The Sudanese government severed diplomatic relations with the UAE due to its alleged support for the RSF.
== Education and certification == Pathologists' assistants have been employed in pathology labs for over 40 years. Formal training programs slowly appeared (there were four nationwide in the late 1990s). NAACLS began accrediting PathA programs in the late 1990s, and then programs slowly continued their transitions from bachelor's to master's programs as their number increased. Prior to ASCP certification, which came about in 2005, the AAPA had a fellowship status that program trained pathologists' assistants or on-the-job trained (OJT) pathologists' assistants (who could do specific coursework and three years of active employment) could join only based on passing a rigorous exam that parallels the current ASCP certification exam. The OJT route was eliminated at the end of 2007. The professional association uniting PAs is the American Association of Pathologists' Assistants. Part of their duties as an association is to provide continuing medical education credits (CME) in order to keep members current on advances and procedures in the field that must be completed every three years in order to maintain ASCP certification.
== Industrial applications == Although the use of protecting groups is not preferred in industrial syntheses, they are still used in industrial contexts, e.g. sucralose (sweetener) or the Roche synthesis of oseltamivir (Tamiflu, an antiviral drug) An important example of industrial applications of protecting group theory is the synthesis of ascorbic acid (Vitamin C) à la Reichstein.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.